Compare CHMI & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | ASRT |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 69.2M |
| IPO Year | 2013 | 1997 |
| Metric | CHMI | ASRT |
|---|---|---|
| Price | $2.49 | $0.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.75 | ★ $3.00 |
| AVG Volume (30 Days) | 290.8K | ★ 755.4K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 16.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $40,202,000.00 | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.73 | N/A |
| P/E Ratio | $132.37 | ★ N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $2.17 | $0.51 |
| 52 Week High | $3.68 | $1.04 |
| Indicator | CHMI | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 49.01 |
| Support Level | $2.20 | $0.65 |
| Resistance Level | $2.52 | $0.79 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 88.57 | 84.21 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.